Pharmaceutical Executive-11-01-2004

Pharmaceutical Executive

Feeling No Pain

November 01, 2004

Features

Lifecycle management and line extensions helped the Percocet franchise generate steady annual growth, rising from $40 million in 1997 sales to $214 million in 2003, despite the fact that it had no patent protection.

AfterShoxx

November 01, 2004

Features

We didn't think, even before Vioxx got pulled, that Arcoxia would ever get approved because we thought it had cardiovascular signals-and because of the debate over Vioxx for the last five years. Now, unequivocally, we don't believe it will be approved.

New Questions on Safety

November 01, 2004

Washington Report

Finger pointing has begun in earnest, as Congress tries to decide who ignored what warning, who silenced what staff scientist, and who broke what law. But recent events also raise real long-term issues for industry.

TOC

November 01, 2004

Patient Centric